Literature DB >> 15735803

Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension.

Diana Bonderman1, Johannes Jakowitsch, Christopher Adlbrecht, Michael Schemper, Paul A Kyrle, Verena Schönauer, Markus Exner, Walter Klepetko, Meinhard P Kneussl, Gerald Maurer, Irene Lang.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by organized thromboemboli that obstruct the pulmonary vascular bed. Although CTEPH is a serious complication of acute symptomatic pulmonary embolism in 4% of cases, signs, symptoms and classical risk factors for venous thromboembolism are lacking. The aim of the present study was to identify medical conditions conferring an increased risk of CTEPH. We performed a case-control-study comparing 109 consecutive CTEPH patients to 187 patients with acute pulmonary embolism that was confirmed by a high probability lung scan. Splenectomy (odds ratio=13, 95% CI 2.7-127), ventriculo-atrial (VA-) shunt for the treatment of hydrocephalus (odds ratio=13, 95% CI 2.5-129) and chronic inflammatory disorders, such as osteomyelitis and inflammatory bowel disease (IBD, odds ratio=67, 95% CI 7.9-8832) were associated with an increased risk of CTEPH.

Entities:  

Mesh:

Year:  2005        PMID: 15735803     DOI: 10.1160/TH04-10-0657

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  35 in total

Review 1.  Classification and diagnosis of pulmonary hypertension.

Authors:  Hector R Cajigas; Rana Awdish
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  The connection between pulmonary embolism and chronic thromboembolic pulmonary hypertension: research session at the American Thoracic Society 2016 Meeting.

Authors:  Timothy Morris
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  Surgical management of pancreatic neuroendocrine tumors.

Authors:  Wataru Kimura; Koji Tezuka; Ichiro Hirai
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

4.  Should not we be using aspirin in patients with a ventriculoatrial shunt? Borrowing a leaf from other specialities: a case for surrogate evidence.

Authors:  Suhas Udayakumaran; Shine Kumar
Journal:  Childs Nerv Syst       Date:  2020-10-08       Impact factor: 1.475

5.  Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis.

Authors:  Shelley E Crary; Sarah Troendle; Naveed Ahmad; George R Buchanan
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

6.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

7.  Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism.

Authors:  Frederikus A Klok; Klaas W van Kralingen; Arie P J van Dijk; Fenna H Heyning; Hubert W Vliegen; Menno V Huisman
Journal:  Haematologica       Date:  2010-01-06       Impact factor: 9.941

Review 8.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 9.  Chronic Thromboembolic Pulmonary Hypertension: Pearls and Pitfalls of Diagnosis.

Authors:  Humna Abid Memon; C Huie Lin; Ashrith Guha
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 10.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.